Executive Summary
Forzinity—greenlit late Friday under the FDA's accelerated approval pathway Sep 23, 2025—TheFDAhas granted acceleratedapprovalfor the elamipretide injection, the first treatment forBarth syndromein patients weighing at
In a landmark decision for patients and families affected by a rare genetic disorder, the U.S. Food and Drug Administration (FDA) has granted accelerated approval to elamipretide, making it the first approved therapy for Barth syndrome. The drug will be marketed as Forzinity (elamipretide HCl). This significant approval marks a pivotal moment in the treatment of this ultra-rare mitochondrial disease, offering hope and a tangible therapeutic option where none previously existed.
Barth syndrome is a debilitating X-linked genetic disorder that primarily affects males. It is characterized by a range of serious health issues, including muscle weakness, fatigue, recurrent infections, and significant heart abnormalities. The underlying cause of Barth syndrome lies in a defect in cardiolipin metabolism, which impairs the function of mitochondria, the powerhouses of the cell. This mitochondrial dysfunction leads to a cascade of problems affecting various organ systems, most notably the heart and skeletal muscles.
The journey to FDA approval for Forzinity has been a long and dedicated one, driven by tireless advocacy and extensive research. Stealth BioTherapeutics, the biotechnology company behind the development of elamipretide, has been instrumental in bringing this novel therapy to patients. The FDA's accelerated approval pathway was utilized for elamipretide, a process designed to expedite the availability of drugs for serious or life-threatening conditions that address unmet medical needs. This pathway was pursued following a strong recommendation from an FDA Advisory Committee, which concluded that elamipretide was effective for the treatment of Barth syndrome. One patient, Carter, who sent a letter to the FDA urging approval of the drug, has seen its life-saving potential in his home state of Georgia.
FORZINITY, the first treatment option for Barth syndrome, is a mitochondria-targeted peptide. Specifically, Elamipretide (SS-31) is the first mitochondria-targeted peptide to get FDA clearance. Clinical studies have demonstrated the drug's ability to improve mitochondrial function. Data from these trials indicate that elamipretide can improve mitochondria function and boost muscle strength by an impressive 45% and heart function by 40% in patients with Barth syndrome. This improvement in cellular energy production and organ function is crucial for alleviating the severe symptoms associated with the condition.
The FDA approval is for Forzinity to improve muscle strength in both adult and pediatric patients diagnosed with Barth syndrome who weigh at least 30 kilograms. The approval was granted under accelerated approval by the U.S. Food and Drug Administration (FDA). While the FDA approved the drug for Barth syndrome despite some earlier findings by its data reviewers that the treatment, while safe, was not definitively more effective, the overall clinical data supported its approval for this rare disease. This decision signifies a major breakthrough, not just for the Barth syndrome community but for all individuals affected by mitochondrial disease.
The Forzinity (elamipretide) gains FDA accelerated approval as a significant milestone. The FDA approves peptide therapy for Barth syndrome, a development that was widely anticipated. The FDA approval for Forzinity (elamipretide) was initially met with some delays in decision-making, with reports of the FDA decision on Barth syndrome therapy delayed again. However, Stealth wins US FDA approval of first Barth syndrome drug, with Forzinity—greenlit late Friday under the FDA's accelerated approval pathway—standing as the first FDA-authorized mitochondria-targeted treatment for the condition. The FDA approved elamipretide (Forzinity), a testament to the years of research and advocacy.
The elamipretide FDA approval date is a date that will be etched in medical history for Barth syndrome. This approval signifies a new era of treatment, offering a tangible benefit and improved quality of life for those affected by this rare and challenging disease. The FDA's decision to grant accelerated approval underscores the urgent need for effective therapies for ultra-rare conditions like Barth syndrome.
Related Articles
Frequently Asked Questions
Here are the most common questions about .
Leave a Comment
Share your thoughts, feedback, or additional insights on this topic.
